T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Book ChapterDOI
Identification of Proteins Required for Ca2+-Triggered Secretion
TL;DR: The identification of several key protein participants represents an important step toward understanding the biochemical events underlying membrane fusion, and a large number of genes required in the yeast secretory pathway have been identified by mutational analysis.
Journal ArticleDOI
HDAC inhibition modulates cardiomyocyte contractility and myofilament acetylation
Deborah M Eaton,Thomas Martin,Michael Kasa,Natasa Djalinac,Jaslyn Johnson,Ewald Kolesnik,Senka Ljubojevic-Holzer,Dirk von Lewinski,Maria Poettler,Theerachat Kampaengsri,H. Maechler,Andreas Zirlik,Timothy A. McKinsey,Jonathan A. Kirk,Steven R. Houser,Peter R Rainer,Markus Wallner +16 more
Journal ArticleDOI
B06: subcutaneous talquetamab in combination with daratumumab in patients with relapsed/refractory multiple myeloma (rrmm): phase 1b results
Maria-Victoria Mateos,Patil Udaysing Hari,N. Bahlis,Ajai Chari,N. W. van de Donk,Bhagirathbhai Dholaria,Alfred L. Garfall,Hartmut Goldschmidt,Klaus Martin Kortüm,Amrita Krishnan,Thomas Martin,Daniel Morillo,Albert Oriol,Donna E. Reece,Cristian Rodriguez,Paula Rodriguez-Otero,J. San Miguel,S. Usmani,Raluca I. Verona,TJ Prior,Margaret Gaston Wade,Brendan M. Weiss,David J. Goldberg,Elham Askari +23 more
TL;DR: This research presents a novel and scalable approach called “Smart Tumor Engineering”, which aims to provide real-time information about the “building blocks” of tumourigenicity and its role in disease progression.
Journal ArticleDOI
P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Philippe Moreau,Saad Z. Usmani,N. W. C. J. van de Donk,Alfred L. Garfall,Michel Delforge,Albert Oriol,Ajay K. Nooka,Laura Rosiñol,Nizar J. Bahlis,Paula Rodriguez-Otero,Thomas Martin,Joris Diels,Suzy Van Sanden,Lixia Pei,Eric A. Ammann,Rachel Kobos,A. Marshall,Mary Slavcev,Jennifer Smit,Anil Londhe,Amrita Krishnan +20 more
Journal ArticleDOI
B05: results from a meta-analysis of ciltacabtagene autoleucel compared to physician’s choice of treatment in patients with relapsed or refractory multiple myeloma
F. Gay,J. Berdeja,Virgilio De Stefano,Petra Hari,B. Hooper,Anja Haltner,Sunil Kumar,Thomas Martin,M.V. Mateos,Philippe Moreau,Emily Rosta,IA Samjoo,S. Usmani,Katja Weisel,C. Jackson,Yunsi Olyslager,J. Schecter,Martin Vogel,A. Garrett,S. Lee,Tonia Nesheiwat,Lida Bubuteishvili Pacaud,Satish Valluri,L. Costa,Yi Lin +24 more
TL;DR: In MM cell lines, the lytic activity of Tec was enhanced by pretreatment and combination treatment with Dara; thus, the combination of both agents may improve efficacy in RRMM by targeting discrete yet complementary antigens.